Home
    • Plans Blog Contact
    Adial Pharmaceuticals Inc logo

    Adial Pharmaceuticals Inc

    ADIL
    Last price US$2.86
    Market cap US$4.2m
    12M price change -77.57%
    Loading the 12-month Mave Thesis and 1-month news signal

    Industry and sector peers, plus broader research alternatives

    View comparison
    Halozyme Therapeutics IncHALO Industry peer Corcept Therapeutics IncorporatedCORT Industry peer Exelixis IncEXEL Industry peer Zoetis IncZTS Sector peer
    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    Adial Pharmaceuticals Inc Overview

    Industry: Biotechnology

    Sector: Healthcare

    Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia. Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcoho Read More

    Mavefund brings filings, fundamentals, valuation, price history and news for Adial Pharmaceuticals Inc into one research view. The sections below show what strengthens or weakens the research case.

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed May 11, 2026

    Quarterly result summary

    Net loss was -$2M (from $2.2M). Cash was $4.6M.

    Net loss -$2M from $2.2M
    Cash $4.6M reported

    What changed

    • Net loss was -$2M (from $2.2M).

    Guidance / outlook

    No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.

    Earnings release Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    SEC filing CURRENT REPORT May 11, 2026 SEC filing QUARTERLY REPORT May 08, 2026 Earnings release PRESS RELEASE ISSUED BY ADIAL PHARMACEUTICALS, INC., MARCH 6, 2026 Mar 06, 2026 SEC filing CURRENT REPORT Mar 06, 2026 SEC filing ANNUAL REPORT Mar 05, 2026 SEC filing CURRENT REPORT Nov 14, 2025 Earnings release PRESS RELEASE, ISSUED BY ADIAL PHARMACEUTICALS, INC. ON NOVEMBER 14, 2025 Nov 14, 2025 SEC filing QUARTERLY REPORT Nov 13, 2025 Earnings release PRESS RELEASE, ISSUED BY ADIAL PHARMACEUTICALS, INC. ON AUGUST 14, 2025 Aug 14, 2025 SEC filing CURRENT REPORT Aug 14, 2025 SEC filing QUARTERLY REPORT Aug 13, 2025

    Prediction-grade evidence

    Recent News

    Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.

    | Associated Press Of Pakistan

    Principal Information Officer Raisa Adil being presented with a shield at the National Press Club by President Abdul Razzaq Sial and Finance Secretary Abid Abbasi on her arrival at the National Press Club.

    Headline from | Associated Press Of Pakistan: Principal Information Officer Raisa Adil being presented with a shield at the National Press Club by President Abdul Razzaq Sial and Finance Secretary Abid Abbasi on her arrival at the National Press Club.

    Earnings Per Share

    Score 1.00/5
    Adial Pharmaceuticals Inc earns a low score, as its Earnings Per Share (EPS) has not shown continuous growth over the last six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    In Biotechnology industry , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated , Exelixis Inc are companies with high ratings.

    Return on Equity

    Score 0.08/5
    Adial Pharmaceuticals Inc exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Adial Pharma... ADIL US$4.2m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Net Margin

    Score 2.21/5
    Adial Pharmaceuticals Inc olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Adial Pharma... ADIL US$4.2m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Share Buyback

    In Biotechnology industry , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated , Exelixis Inc are companies with high ratings.

    Leverage

    Score 3.08/5
    Adial Pharmaceuticals Inc attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc , also exhibit high scores.
    Adial Pharma... ADIL US$4.2m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    Verified SEC statements load when this section enters view.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    Adial Pharmaceuticals Inc logo

    Adial Pharmaceuticals Inc

    US$2.86

    US$4.2m

    4.76%

    -77.57%